Galapagos N.V. (GLPG) |
| 27.98 0.47 (1.71%) 06-04 11:58 |
| Open: | 27.5 |
| High: | 28.09 |
| Low: | 27.5 |
| Volume: | 2,385 |
| Market Cap: | 1,844(M) |
| PE Ratio: | 3.21 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 34.50 |
| Resistance 1: | 29.53 |
| Pivot price: | 28.63 |
| Support 1: | 27.92 |
| Support 2: | 26.92 |
| 52w High: | 37.78 |
| 52w Low: | 24.74 |
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Financials
| EPS | 8.710 |
| Book Value | 2.900 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.551 |
| Profit Margin (%) | 46.83 |
| Operating Margin (%) | -982.92 |
| Return on Assets (ttm) | 10.7 |
| Return on Equity (ttm) | 16.3 |
Company news
Tue, 18 Aug 2026
Galapagos Nv Live Share Prices and Trades. GLPG.US Live Streaming Share Prices. - London South East
Tue, 11 Aug 2026
GLPG Q1 2026 Earnings: 142.7% EPS Surprise Swings to Profitability - Dividend Cut Risk - vinanet.vn
Sat, 20 Jun 2026
Galapagos NV (GLPG) Holds Steady Near Support – What’s Next for the Biotech Stock? - Volatility Stop - dars.gov.et
Fri, 24 Apr 2026
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1 - Yahoo Finance
Sat, 04 Apr 2026
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets - Yahoo Finance
Thu, 26 Mar 2026
Galapagos NV (GLPG) Releases Q4 2025 Earnings: Revenue and Gross-Profit Surge, But Operating and Net Losses Persist - Quiver Quantitative
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
